Cargando…
Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman
A 63-year-old woman previously stable on a regimen of atorvastatin 40 mg daily, carvedilol 25 mg twice daily, digoxin 0.125 mg daily, furosemide 40 mg daily, spironolactone 25 mg daily, rivaroxaban 15 mg daily, and enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after...
Autores principales: | Faber, Eve S., Gavini, Madhavi, Ramirez, Ronald, Sadovsky, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089965/ https://www.ncbi.nlm.nih.gov/pubmed/27804100 http://dx.doi.org/10.1007/s40800-016-0036-6 |
Ejemplares similares
-
Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)
por: Eadie, Ashley L., et al.
Publicado: (2021) -
Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
por: Nikolic, Marina, et al.
Publicado: (2022) -
Sacubitril‐valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO‐SAS study
por: Jaffuel, Dany, et al.
Publicado: (2021) -
Approaches to management of rhabdomyolysis as the adverse effect of drug interaction between atorvastatin and sacubitril/valsartan: a case report
por: Siew, Kelvin Shenq Woei, et al.
Publicado: (2022) -
Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
por: Jaffuel, Dany, et al.
Publicado: (2018)